Axpira is a bronchodilator with Swiss short-acting beta-2 agonist particulate technology to mitigate asthmatic symptoms1, administered by inhalation. It can also be used for prophylaxis and treatment of bronchial asthma, bronchospasm associated with bronchitis and emphysema. It is CE 0344 certified in compliance with European regulation
An adequate inhalation technique should be used to ensure synchronization between the atomization of the drug and the aspiration, thus ensuring an optimal delivery of Axpira to the lungs.
It is contraindicated in patients with hypersensitivity to the drug, treatment of abortion, premature labor or first trimester of pregnancy. It should be used with caution in patients with hypertension, heart failure or thyrotoxicosis
Provides relief over a three-hour perio
Mitigates asthmatic symptoms
AXPIRA HFA 100 SALBUTAMOL
- Erdinç M. (2011). Beta-2 agonist discussions in asthma and a review of current data. Tuberkuloz ve toraks, 59(2), 205–212.
Phone: + 601 616 0255